# Triventures

> Triventures is a VC fund in Herzliya backing Health Care and Medical Device. See 60 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Herzliya, Israel
- Total investments: 60
- Last investment: Dec 2024
- Lead investor: 30%
- Last fund: Dec 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/triventures
- X (Twitter): https://twitter.com/TriventuresVC
- Website: https://www.triventures.vc

Triventures is a global venture capital firm that invests in startups led by exceptional entrepreneurs. The fund identifies cross-industry breakthroughs that converge the best in class in health and non-health technologies such as insurtech and fintech for healthcare, e-commerce and cyber for healthcare, community-driven genomics, health datamarketplaces, and more. Triventures’ team is comprised of key opinion leaders in healthcare, entrepreneurship, venturing and corporate business development and has decades of accumulated industry experience and relationships.Triventures was founded in 2010 and is headquartered in Herzliya, Tel Aviv, Israel with offices in California, U.S.

## Contacts

5 contacts available for Triventures. Shizune tracks 5 team members at Triventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/triventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $6M–$24M |
| Series B | $6M–$28M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 24 | 40% |
| Medical Device | 13 | 22% |
| Medical | 11 | 18% |
| Wellness | 6 | 10% |
| Fitness | 5 | 8% |

46 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 10 | 17% |
| Series B | 10 | 17% |
| Funding Round | 10 | 17% |
| Seed | 7 | 12% |
| Series C | 6 | 10% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 16 | 27% |
| Israel | 12 | 20% |
| Ireland | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Dani Goldsher | Partner and CFO | 0 | https://shizune.co/investors/profile/dani-goldsher |
| Dr. Peter Fitzgerald | Co-Founder and Managing Partner | 6 | https://shizune.co/investors/profile/peter-fitzgerald-2 |
| Martin Leon | Co-Founder and Venture Partner | 0 | https://shizune.co/investors/profile/martin-leon |
| Michal Geva | Co-Founder and Managing Partner | 8 | https://shizune.co/investors/profile/michal-geva-2 |
| Netalie Nadivi | General Partner | 13 | https://shizune.co/investors/profile/netalie-nadivi |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cala Health | Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company's wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. The first indication for Cala Health's wearable therapy is an essential tremor, adisease experienced by more than seven million people and characterized by severe hand tremors. New therapies are under development in neurology, cardiology, and psychiatry. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology. |  |  | Dec 09, 2024 |  |
| Cala Health | Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company's wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. The first indication for Cala Health's wearable therapy is an essential tremor, adisease experienced by more than seven million people and characterized by severe hand tremors. New therapies are under development in neurology, cardiology, and psychiatry. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology. | $50M | Series C | Dec 09, 2024 |  |
| TailorMed | TailorMed is a health IT company that works with providers, pharmacies and manufacturers to reduce patient financial toxicity and create efficiencies across the patient treatment lifecycle. Our end-to-end platform applies algorithms and automations to make the co-pay assistance and free drug order processes seamless and leverages our deep data setto create actionable insights. | $27.5M | Series B | Nov 21, 2024 |  |
| Grin | Grin is a comprehensive digital orthodontic platform providing teeth straightening for all types of patients with a real local orthodontist. The platform also connects patients with a real orthodontist from the convenience of their smart device. They deliver responsible care from orthodontic specialists in an easily accessible and cost-effectiveway, Grin provides patients quality care that results in an exceptional smile together with all of the modernized convenience that they expect.Grin technology, aligned with a network of local trusted orthodontists, ensures that every patient gets the right care. The platform Grin App and Grin Scope is a patent-pending technology that offers remote monitoring for a variety of orthodontic needs. The Grin experience includes high-quality self-scans with the latest teeth straightening solutions. Practitioners and patients can now use these telemedicine tools to achieve a new, more convenient treatment journey.It was founded by Dr. Adam Schulhof, Pamela Oren-Artzi, and Alon Lipnik in 2019 and is based in New York and Austin. |  |  | Oct 28, 2024 |  |
| Monogoto | Monogoto is a cloud-based cellular network. Its API-driven Infrastructure-as-a-Service was designed from the ground up with simplicity in mind to enable cellular connectivity with existing enterprise IT infrastructure. With hundreds of ready-to-use APIs, Monogoto offers cellular connectivity with edge to the cloud security for IoT, Private LTE, and5G use cases. Its services include full audit for all network events with anomaly detection and alerts automation. Monogoto’s enterprise-friendly solution enables customers to consume advanced cellular VAS with zero CAPEX and an “as-a-Service” business model. The Monogoto network is distributed globally with public connectivity in 180 countries. Helping companies to comply with regulation, the Monogoto solution supports on-premise local breakout topology for private LTE/5G networks. | $27M | Series A | Oct 15, 2024 |  |
| Brightside Health | Brightside Health is a mental health care company that helps employees better navigate and manage their financial well-being. The company makes it simple and affordable to get expert, personalized treatment for depression and anxiety all from the comfort of home. Their mission is to help people lead healthy, vital, and productive lives by making iteasy and affordable to get high-quality depression and anxiety care.Brightside was founded in 2017 and is headquartered in San Francisco, California, United States. | $33M | Series C | Mar 26, 2024 |  |
| BioProtect | BioProtect Ltd. is an international medical device startup. It is primarily engaged in to the business of developing and commercializing biodegradable balloon spacers for the protection of normal tissue during cancer radiation therapy. The company's current focus in the growing radiotherapy spacers market, where its ProSpace balloon spacer (CEmarked) has shown superior efficacy and safety in protecting the rectum during radiation therapy for prostate cancer. The company's technology platform of biodegradable implantable balloons suits a wide range of applications for unmet clinical needs. BioProtect was founded in the year 2004 and headquartered in Israel, with subsidiaries in Germany and US. | $28M |  | Sep 27, 2023 |  |
| Flow Specialty | The smart digital marketplace for commercial risk, empowering insurance professionals to BROKER BETTER.Capitola's platform optimizes distribution efficiency through placement process automation and AI-driven risk appetite matching so that broker teams can focus on what they do best: strengthen relationships, expand their client base, andclose more deals. | $15.6M | Series A | Apr 17, 2023 |  |
| FEMSelect | FEMSelect is making a lasting impact on women's health by delivering an innovative technology platform. It is the developer of EnPlace, a minimally invasive and mesh-free system for pelvic floor ligament fixation. Using EnPlace takes approximately 30 minutes. The patented delivery system enables the precise guidance, insertion, anddeployment of the anchor unit. The anchor is designed to be introduced through the vaginal wall and secured to the pelvic floor ligament to provide stabilization.FEMSelect was founded in 2012 and is headquartered in Modi’in, Israel. | $9M | Series B | Oct 19, 2022 |  |
| Future Family | Future Family is a subscription fertility company, offering easy plans for IVF and egg freezing, with on-demand medical support through Concierge Care. With Future Family, women, men, and couples experience stress-free fertility.Future Family was founded in 2016 by Claire Tomkins and Eve Blossom and is based in San Francisco, California, UnitedStates. | $25M | Series B | Apr 04, 2022 |  |

10 of 60 investments shown.

## Co-investors
- [Triventures](https://shizune.co/investors/profile/triniventures) — VC Fund, 35 deals together
- [Pontifax](https://shizune.co/investors/profile/pontifax) — VC Fund, 8 deals together
- [Johnson & Johnson Innovation](https://shizune.co/investors/profile/johnson-johnson-innovation-jjdc) — VC Fund, 5 deals together
- [BioStar Capital](https://shizune.co/investors/profile/biostar-private-equity) — VC Fund, 4 deals together
- [BRM Capital](https://shizune.co/investors/profile/brm-capital) — VC Fund, 4 deals together
- [Cerca Partners](https://shizune.co/investors/profile/cerca-partners) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [OurCrowd](https://shizune.co/investors/profile/ourcrowd) — VC Fund
- [Entrée Capital](https://shizune.co/investors/profile/entree-capital) — VC Fund
- [Pitango VC](https://shizune.co/investors/profile/pitango-venture-capital) — VC Fund

## Featured in investor lists
- [Wellness Investors](https://shizune.co/investors/wellness-investors)
- [Wellness VC Funds](https://shizune.co/investors/wellness-vc-funds)
- [Fitness Investors](https://shizune.co/investors/fitness-investors)
- [Fitness VC Funds](https://shizune.co/investors/fitness-vc-funds)
- [Health Care Investors in Middle East](https://shizune.co/investors/health-care-investors-middle-east)
- [Health Care VC Funds in Middle East](https://shizune.co/investors/health-care-vc-funds-middle-east)

## FAQ

### What does Triventures invest in?

Triventures invests primarily in Health Care, Medical Device and Medical startups, most often at Series A and Series B stage. Most of the 60 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Triventures's check size?

Triventures typically joins rounds of $6M–$24M at Series A and $6M–$28M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Triventures participates in.

### How do I contact Triventures?

Public channels for Triventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Triventures?

The team at Triventures includes Dani Goldsher (Partner and CFO), Dr. Peter Fitzgerald (Co-Founder and Managing Partner) and Martin Leon (Co-Founder and Venture Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co